ABACAVIR SULFATE (abacavir) by Aurobindo Pharma is 12. Approved for human immunodeficiency virus (hiv-1) infection, combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2012.
Drug data last refreshed 19h ago
12.1 Mechanism of Action Abacavir is an antiretroviral agent [see ] . 12.3 Pharmacokinetics Pharmacokinetics in Adults The pharmacokinetic properties of abacavir were independent of dose over the range of 300 to 1,200 mg per day. Absorption: Following oral administration, abacavir is rapidly…
Worked on ABACAVIR SULFATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites
A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)
Platelet Function on Abacavir and Tenofovir